| Popis: |
Objectives: To evaluate the efficacy and safety of Neoretin Discrom Control Serum for the treatment of melasma.Methods: A clinical trial in 36 melasma patients treated with Neoretin Discrom Control Serum for 4 months. Patients were re-examined at weeks 4, 8, 12, 16; Facial pictures by digital camera were taken and were evaluated the improvement of melasma on the MASI scale, on dermoscopy, the change in Melanin index through the Mexameter, clinical side effects and patient satisfaction during and after treatment was noted.Results: Melasma treatment with Neoretin Discrom Control Serum resulted in a 64% reduction in MASI (from 15.23 to 5.52) after 4 months of treatment. Melanin index measured by Mexameter also decreased after 4 months with a reduction rate of 30.4%. The most common undesirable effect is a stinging sensation (52.8%). Other side effects include itching, burning, redness, dry skin, scaling, acne, and hyperpigmentation. Side effects were encountered mainly in the first month and were mild-moderate. No serious side effects and no systemic side effects were detected. After 4 months of treatment, the patient’s self-rated melasma lesions improved by 46%, with an average satisfaction score of 7.8/10.Conclusion: Neoretin Discrom Control Serum proved to be an effective and safe product for the treatment of melasma. It should be combined with moisturizers and skin-soothing creams to minimize unwanted effects. |
